On Tuesday, Prime Medicine Inc (NASDAQ: PRME) was 5.56% up from the session before settling in for the closing price of $3.96. A 52-week range for PRME has been $3.28 – $9.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. When this article was written, the company’s average yearly earnings per share was at 24.49%. With a float of $39.57 million, this company’s outstanding shares have now reached $97.38 million.
Let’s look at the performance matrix of the company that is accounted for 234 employees. In terms of profitability, gross margin is 94.66%, operating margin of -560.15%, and the pretax margin is -545.19%.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Prime Medicine Inc stocks. The insider ownership of Prime Medicine Inc is 67.03%, while institutional ownership is 36.26%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 24.49% per share during the next fiscal year.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
You can see what Prime Medicine Inc (PRME) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 850.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.13, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Prime Medicine Inc (NASDAQ: PRME) saw its 5-day average volume 0.61 million, a negative change from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 41.21%. Additionally, its Average True Range was 0.31.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 19.40%, which indicates a significant decrease from 61.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.58% in the past 14 days, which was higher than the 86.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.88, while its 200-day Moving Average is $5.65. Nevertheless, the first resistance level for the watch stands at $4.30 in the near term. At $4.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.64. If the price goes on to break the first support level at $3.96, it is likely to go to the next support level at $3.73. The third support level lies at $3.62 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are 120,031K outstanding shares of the company, which has a market capitalization of 501.73 million. As of now, sales total 0 K while income totals -198,130 K. Its latest quarter income was 590 K while its last quarter net income were -45,760 K.
